Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPill

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 50-79 years old~* Enrollment in the Golestan Cohort Study~Exclusion Criteria:~1. Hypersensitivity to any of PolyPill components:~   1. Hypersensitivity to Non-steroidal anti-inflammatory agents~  2. Hypersensitivity to statins~  3. Hypersensitivity to hydrochlorothiazide or sulfonamides~  4. Hypersensitivity to enalapril and valsartan~2. Past medical history of angioedema~3. Medical history of GI bleeding or peptic ulcer in the last 3 months~4. Pregnancy or lactation~5. Bleeding disorders such as hemophilia~6. Receiving anticoagulation therapy~7. Alcohol consumption greater than 40gr/week~8. Advanced liver disease~9. Uncontrolled seizures~10. Asthma with any of the following criteria present:~    1. Daily symptoms~   2. Asthmatic attacks waking the patient from sleep more than once a week~   3. History of nasal polyps~   4. Aspirin sensitive asthma~   5. Presence of rhinitis symptoms not due to infection~11. Past medical history of gout~12. Serum creatinine values above 2 mg/dL or a Glomerular Filtration Rate (GFR) below 30 mL/min~13. Hemoglobin concentrations below 11 g/dL for males and 10 g/dL for females~14. BP \< 90/60~15. Debilitating medical/mental disorders affecting medication compliance (including psychosis, disabilities, and blindness)~16. Past medical history of stroke

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- PolyPill (Type: ACTIVE_COMPARATOR): PolyPill once daily and Minimal Care
- Minimal care (Type: ACTIVE_COMPARATOR): Minimal care.
- Usual care (Type: NO_INTERVENTION): Basic primary health care provided by the local physicians and Community Health Workers consistent with the current Iranian Health Care System guidelines.

Based on this trial design, predict the completion outcome and termination type (if applicable).